People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...
Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin sites for new plants beyond a $3 billion project the ...
Eli Lilly And Co (NYSE:LLY) announced a $3 billion expansion of its Kenosha County, Wisconsin, manufacturing facility to ...
Given the strong demand expected for Eli Lilly's (NYSE:LLY) weight loss treatment Zepbound (tirzepatide) in the UK, the ...
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...